PROCTER & GAMBLE HEALTH | ADVANCED ENZYME TECHNOLOGIES | PROCTER & GAMBLE HEALTH/ ADVANCED ENZYME TECHNOLOGIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.6 | 31.5 | 110.0% | View Chart |
P/BV | x | 10.6 | 3.5 | 297.7% | View Chart |
Dividend Yield | % | 2.0 | 1.3 | 157.4% |
PROCTER & GAMBLE HEALTH ADVANCED ENZYME TECHNOLOGIES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
ADVANCED ENZYME TECHNOLOGIES Mar-23 |
PROCTER & GAMBLE HEALTH/ ADVANCED ENZYME TECHNOLOGIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 328 | 1,634.1% | |
Low | Rs | 3,883 | 225 | 1,725.8% | |
Sales per share (Unadj.) | Rs | 740.7 | 48.3 | 1,532.1% | |
Earnings per share (Unadj.) | Rs | 138.2 | 9.3 | 1,488.2% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 12.4 | 1,249.2% | |
Dividends per share (Unadj.) | Rs | 95.00 | 5.00 | 1,900.0% | |
Avg Dividend yield | % | 2.1 | 1.8 | 113.7% | |
Book value per share (Unadj.) | Rs | 447.6 | 110.5 | 405.3% | |
Shares outstanding (eoy) | m | 16.60 | 111.82 | 14.8% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 5.7 | 109.1% | |
Avg P/E ratio | x | 33.5 | 29.8 | 112.3% | |
P/CF ratio (eoy) | x | 29.8 | 22.3 | 133.8% | |
Price / Book Value ratio | x | 10.3 | 2.5 | 412.4% | |
Dividend payout | % | 68.7 | 53.8 | 127.7% | |
Avg Mkt Cap | Rs m | 76,761 | 30,939 | 248.1% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 1,148 | 179.6% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 5,406 | 227.4% | |
Other income | Rs m | 184 | 255 | 72.2% | |
Total revenues | Rs m | 12,480 | 5,661 | 220.5% | |
Gross profit | Rs m | 3,247 | 1,534 | 211.6% | |
Depreciation | Rs m | 281 | 350 | 80.2% | |
Interest | Rs m | 8 | 35 | 22.1% | |
Profit before tax | Rs m | 3,142 | 1,404 | 223.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 365 | 232.0% | |
Profit after tax | Rs m | 2,295 | 1,039 | 220.9% | |
Gross profit margin | % | 26.4 | 28.4 | 93.0% | |
Effective tax rate | % | 27.0 | 26.0 | 103.7% | |
Net profit margin | % | 18.7 | 19.2 | 97.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 7,221 | 162.2% | |
Current liabilities | Rs m | 6,791 | 776 | 875.5% | |
Net working cap to sales | % | 40.0 | 119.2 | 33.6% | |
Current ratio | x | 1.7 | 9.3 | 18.5% | |
Inventory Days | Days | 263 | 255 | 103.1% | |
Debtors Days | Days | 343 | 68 | 507.0% | |
Net fixed assets | Rs m | 10,617 | 6,884 | 154.2% | |
Share capital | Rs m | 166 | 224 | 74.2% | |
"Free" reserves | Rs m | 7,265 | 12,127 | 59.9% | |
Net worth | Rs m | 7,431 | 12,351 | 60.2% | |
Long term debt | Rs m | 0 | 78 | 0.0% | |
Total assets | Rs m | 22,330 | 14,105 | 158.3% | |
Interest coverage | x | 409.1 | 41.4 | 988.9% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.4 | 143.7% | |
Return on assets | % | 10.3 | 7.6 | 135.5% | |
Return on equity | % | 30.9 | 8.4 | 367.2% | |
Return on capital | % | 42.4 | 11.6 | 366.2% | |
Exports to sales | % | 0 | 17.3 | 0.0% | |
Imports to sales | % | 13.1 | 7.8 | 168.1% | |
Exports (fob) | Rs m | NA | 937 | 0.0% | |
Imports (cif) | Rs m | 1,605 | 420 | 382.3% | |
Fx inflow | Rs m | 1,465 | 937 | 156.3% | |
Fx outflow | Rs m | 1,605 | 420 | 382.3% | |
Net fx | Rs m | -140 | 518 | -27.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 1,404 | 168.1% | |
From Investments | Rs m | -215 | -2,982 | 7.2% | |
From Financial Activity | Rs m | -985 | -258 | 381.7% | |
Net Cashflow | Rs m | 1,160 | -1,709 | -67.9% |
Indian Promoters | % | 0.0 | 2.4 | - | |
Foreign collaborators | % | 51.8 | 41.1 | 126.2% | |
Indian inst/Mut Fund | % | 20.0 | 30.6 | 65.3% | |
FIIs | % | 6.2 | 23.0 | 27.1% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 56.5 | 85.3% | |
Shareholders | 56,778 | 68,640 | 82.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | ADVANCED ENZYME TECHNOLOGIES | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.43% | 1.58% | 0.45% |
1-Month | -1.15% | 10.70% | 2.55% |
1-Year | 0.73% | 53.41% | 56.14% |
3-Year CAGR | -8.76% | 0.97% | 15.22% |
5-Year CAGR | 4.97% | 15.03% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the ADVANCED ENZYME TECHNOLOGIES share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of ADVANCED ENZYME TECHNOLOGIES the stake stands at 43.5%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of ADVANCED ENZYME TECHNOLOGIES.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
ADVANCED ENZYME TECHNOLOGIES paid Rs 5.0, and its dividend payout ratio stood at 53.8%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of ADVANCED ENZYME TECHNOLOGIES.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.